Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type of non-Hodgkin's lymphoma (NHL) that
is mostly diagnosed in elderly patients. Its non-specific clinical presentation (lymphadenopathy, fever, night
sweats, weight loss, generalized rash, and hepatosplenomegaly) often results in a delay in the diagnosis. The
diagnosis is mainly established based on a detailed clinical evaluation and biopsy findings, and currently,
available treatment options include corticosteroids, immunotherapy, and single- or multi-agent
chemotherapy. Here, we report a case of a 61-year-old male who presented with complaints of easy
fatigability, dyspnea, and fever along with inguinal lymphadenopathy and was diagnosed as a case of AITL.
He was given multiple cycles of R-CHOP chemotherapy (Cytoxan, Hydroxyrubicin, Oncovin, and Prednisone
chemotherapy regimen), which led to tumor eradication. The patient, however, expired due to unknown
reasons. The case highlights the major diagnostic modalities and treatment strategies for AITL and sheds light
on the poor prognosis of the disease despite adequate management.
